Greg Madison of Shield Therapeutics: Accrufer® US total prescriptions quadrupled in H1 2022
Episode 894, Sep 14, 2022, 08:39 AM
Greg Madison, CEO of Shield Therapeutics #STX provides some highlights from the interim results, which showed Accrufer® US total prescriptions increasing by 350% to 11,223 in H1:2022 compared to 2,516 in H2:2021.
Greg Madison, CEO of Shield Therapeutics #STX provides some highlights from the interim results, which showed Accrufer® US total prescriptions increasing by 350% to 11,223 in H1:2022 compared to 2,516 in H2:2021.
Current Business Update
· Total US Accrufer® prescriptions increased c. 350% to 11,223 in H1:2022 compared to 2,516 in H2:2021:
o Women's health practitioners have written approximately 50% of Accrufer® prescriptions to treat women with underlying diseases leading to iron deficiency and/or iron deficiency anaemia. This segment is growing rapidly.
o General practitioners represent approximately 45% of Accrufer® prescriptions, with demand continuing to grow in this segment as well.
· c.20 million people in the US have anaemia, reflecting a large and continuous unmet medical need.
· Total US net revenue from Accrufer® for H1:2022 increased to US$1.5 million compared to US$0.1 million for H2:2021, which was also the first half year following the launch.
· 1,050 new first time prescribers of Accrufer® during H1:2022, a fivefold increase from January to June 2022, indicating growing awareness and interest by healthcare providers.
· 100 million or ~40% of eligible lives now have coverage for Accrufer® by US payers across Commercial and Medicaid segments, dramatically expanding access for patients.
· c.2,300 Health care providers have been introduced to Accrufer® by participating in Shield-sponsored programmes in H1:2022.
To read the full RNS click here
Current Business Update
· Total US Accrufer® prescriptions increased c. 350% to 11,223 in H1:2022 compared to 2,516 in H2:2021:
o Women's health practitioners have written approximately 50% of Accrufer® prescriptions to treat women with underlying diseases leading to iron deficiency and/or iron deficiency anaemia. This segment is growing rapidly.
o General practitioners represent approximately 45% of Accrufer® prescriptions, with demand continuing to grow in this segment as well.
· c.20 million people in the US have anaemia, reflecting a large and continuous unmet medical need.
· Total US net revenue from Accrufer® for H1:2022 increased to US$1.5 million compared to US$0.1 million for H2:2021, which was also the first half year following the launch.
· 1,050 new first time prescribers of Accrufer® during H1:2022, a fivefold increase from January to June 2022, indicating growing awareness and interest by healthcare providers.
· 100 million or ~40% of eligible lives now have coverage for Accrufer® by US payers across Commercial and Medicaid segments, dramatically expanding access for patients.
· c.2,300 Health care providers have been introduced to Accrufer® by participating in Shield-sponsored programmes in H1:2022.
To read the full RNS click here